The GENIE Registry is a publicly available, continuously evolving repository of real-world clinico-genomic data, currently housing: 

• 230,000+ clinical-grade genomic samples from more than 200,000 patients, with an annual addition of approximately 30,000 new patients. 
• High-fidelity clinico-genomic data from academic tertiary referral centers. 
• An internationally representative dataset, including both U.S. and ex-U.S. patient populations. 
• New analytes as the genomic landscape matures. 

The unique quality and breadth of GENIE data make it a powerful resource for: 

• Biomarker-driven Strategies – Identifying and validating predictive biomarkers. 
• Clinical Trial Feasibility – Informing trial design and patient stratification. 
• Regulatory Strategy Development – Providing critical RWD for real-world evidence (RWE) generation. 

The GENIE Registry, data derived from leading international cancer centers serving diverse patient populations, offers a solution for validating insights derived from commercial vendors that predominantly rely on community practices. This ensures GENIE RWD is representative of the populations enrolled in late-stage clinical trials. GENIE international footprint, encompassing both US and Ex-US patient populations, delivers a diverse and comprehensive resource that mirrors real-world clinical scenarios.